Emodin protects against diabetic cardiomyopathy by regulating the AKT/GSK-3β Signaling pathway in the Rat Model

Molecules

Volumn 19, Issue 9, 2014, Pages 14782-14793

  Wu, Zhiqin ^a   Chen, Qingwei ^a   Ke, Dazhi ^a   Li, Guiqiong ^a   Deng, Wei ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Akt; Blood glucose; Diabetic cardiomyopathy; Emodin; GSK 3

Indexed keywords

CHOLESTEROL; EMODIN; TRIACYLGLYCEROL;

ANIMAL; BLOOD; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DRUG SCREENING; HEART LEFT VENTRICLE FUNCTION; MALE; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DRUG EVALUATION, PRECLINICAL; EMODIN; MALE; RATS, WISTAR; SIGNAL TRANSDUCTION; TRIGLYCERIDES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84907909017     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules190914782     Document Type: Article

References (46)

1. Matthews, D.R.; Pramming, S. Diabetes and the global burden of non-communicable disease. Lancet 2003, 362, 1763-1764.
2. Kitabchi, A.E.; Umpierrez, G.E.; Miles, J.M.; Fisher, J.N. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009, 32, 1335-1343.
3. Alberti, K.G.; Zimmet, P. Global burden of disease-Where does diabetes mellitus fit in? Nat. Rev. Endocrinol. 2013, 9, 258-260.
4. King, H.; Aubert, R.E.; Herman, W.H. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998, 21, 1414-1431.
5. Roger, V.L.; Go, A.S.; Lloyd-Jones, D.M.; Benjamin, E.J.; Berry, J.D.; Borden, W.B.; Bravata, D.M.; Dai, S.; Ford, E.S.; Fox, C.S.; et al. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation 2012, 125, e2-e220.
6. Witteles, R.M.; Fowler, M.B. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J. Am. Coll. Cardiol. 2008, 51, 93-102.
7. Battiprolu, P.K.; Gillette, T.G.; Wang, Z.V.; Lavandero, S.; Hill, J.A. Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets. Drug Discov. Today: Dis. Mech. 2010, 7, e135-e143.
8. Falcao-Pires, I.; Leite-Moreira, A.F. Diabetic cardiomyopathy: Understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail. Rev. 2012, 17, 325-344.
9. Mano, Y.; Anzai, T.; Kaneko, H.; Nagatomo, Y.; Nagai, T.; Anzai, A.; Maekawa, Y.; Takahashi, T.; Meguro, T.; Yoshikawa, T.; et al. Overexpression of human C-reactive protein exacerbates left ventricular remodeling in diabetic cardiomyopathy. Jpn. Circ. J. 2010, 75, 1717-1727.
10. Wang, J.; Wang, H.; Hao, P.; Xue, L.; Wei, S.; Zhang, Y.; Chen, Y. Inhibition of aldehyde dehydrogenase 2 by oxidative stress is associated with cardiac dysfunction in diabetic rats. Mol. Med. 2011, 17, 172-179.
11. Zhou, H.; Li, Y.J.; Wang, M.; Zhang, L.H.; Guo, B.Y.; Zhao, Z.S.; Meng, F.L.; Deng, Y.G.; Wang, R.Y. Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes. Acta Pharmacol. Sin. 2011, 32, 999-1008.
12. Thandavarayan, R.A.; Watanabe, K.; Ma, M.; Gurusamy, N.; Veeraveedu, P.T.; Konishi, T.; Zhang, S.; Muslin, A.J.; Kodama, M.; Aizawa, Y. Dominant-negative p38alpha mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. Am. J. Physiol.-Heart C 2009, 297, H911-H919.
13. Duncan, J.G. Mitochondrial dysfunction in diabetic cardiomyopathy. BBA-Mol. Cell Res. 2011, 1813, 1351-1359.
14. Chun-Guang, W.; Jun-Qing, Y.; Bei-Zhong, L.; Dan-Ting, J.; Chong, W.; Liang, Z.; Dan, Z.; Yan, W. Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo. Eur. J. Pharmacol. 2010, 627, 33-41.
15. Alisi, A.; Pastore, A.; Ceccarelli, S.; Panera, N.; Gnani, D.; Bruscalupi, G.; Massimi, M.; Tozzi, G.; Piemonte, F.; Nobili, V. Emodin prevents intrahepatic fat accumulation, inflammation and redox status imbalance during diet-induced hepatosteatosis in rats. Int. J. Mol. Sci. 2010, 13, 2276-2289.
16. Lin, S.Z.; Wei, W.T.; Chen, H.; Chen, K.J.; Tong, H.F.; Wang, Z.H.; Ni, Z.L.; Liu, H.B.; Guo, H.C.; Liu, D.L. Antitumor activity of emodin against pancreatic cancer depends on its dual role: Promotion of apoptosis and suppression of angiogenesis. PLoS One 2012, 7, e42146.
17. Zhang, X.; Zhang, R.; Lv, P.; Yang, J.; Deng, Y.; Xu, J.; Zhu, R.; Zhang, D.; Yang, Y. Emodin up-regulates glucose metabolism, decreases lipolysis, and attenuates inflammation in vitro. J. Diabetes 2014, doi:10.1111/1753-0407.12190.
18. Yang, Z.; Zhou, E.; Wei, D.; Li, D.; Wei, Z.; Zhang, W.; Zhang, X. Emodin inhibits LPS-induced inflammatory response by activating PPAR-gamma in mouse mammary epithelial cells. Int. Immunopharmacol. 2014, 21, 354-360.
19. Shuangsuo, D.; Zhengguo, Z.; Yunru, C.; Xin, Z.; Baofeng, W.; Lichao, Y.; Yan?an, C. Inhibition of the replication of hepatitis B virus in vitro by emodin. Med. Sci. Monit. 2006, 12, 302-306.
20. Feng, Y.; Huang, S.L.; Dou, W.; Zhang, S.; Chen, J.H.; Shen, Y.; Shen, J.H.; Leng, Y. Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice. Br. J. Pharmacol. 2010, 161, 113-126.
21. Wang, J.; Huang, H.; Liu, P.; Tang, F.; Qin, J.; Huang, W.; Chen, F.; Guo, F.; Liu, W.; Yang, B. Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats. Eur. J. Pharmacol. 2006, 553, 297-303.
22. Xue, J.; Ding, W.; Liu, Y. Anti-diabetic effects of emodin involved in the activation of PPARgamma on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice. Fitoterapia 2010, 81, 173-177.
23. Gao, J.; Wang, F.; Wang, W.; Su, Z.; Guo, C.; Cao, S. Emodin suppresses hyperglycemia-induced proliferation and fibronectin expression in mesangial cells via inhibiting cFLIP. PLoS One 2014, 9, e93588.
24. Lee, W.; Ku, S.K.; Lee, D.; Lee, T.; Bae, J.S. Emodin-6-O-beta-D-glucoside inhibits high-glucose-induced vascular inflammation. Inflammation 2014, 37, 306-313.
25. Huang, F.J.; Hsuuw, Y.D.; Chan, W.H. Characterization of apoptosis induced by emodin and related regulatory mechanisms in human neuroblastoma cells. Int. J. Mol. Sci. 2014, 14, 20139-20156.
26. Rubler, S.; Dlugash, J.; Yuceoglu, Y.Z.; Kumral, T.; Branwood, A.W.; Grishman, A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 1972, 30, 595-602.
27. Boudina, S.; Abel, E.D. Diabetic cardiomyopathy, causes and effects. Rev. Endocr. Metab. Disord. 2010, 11, 31-39.
28. Bell, D.S. Diabetic cardiomyopathy. Diabetes Care 2003, 26, 2949-51.
29. Cai, L. Diabetic cardiomyopathy and its prevention by metallothionein: Experimental evidence, possible mechanisms and clinical implications. Curr. Med. Chem. 2007, 14, 2193-2203.
30. Voulgari, C.; Papadogiannis, D.; Tentolouris, N. Diabetic cardiomyopathy: From the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc. Health Risk Manag. 2010, 6, 883-903.
31. Fredersdorf, S.; Thumann, C.; Zimmermann, W.H.; Vetter, R.; Graf, T.; Luchner, A.; Riegger, G.A.; Schunkert, H.; Eschenhagen, T.; Weil, J. Increased myocardial SERCA expression in early type 2 diabetes mellitus is insulin dependent: In vivo and in vitro data. Cardiovasc. Diabetol. 2012, 11, 57.
32. . Aragno, M.; Mastrocola, R.; Ghe, C.; Arnoletti, E.; Bassino, E.; Alloatti, G.; Muccioli, G. Obestatin induced recovery of myocardial dysfunction in type 1 diabetic rats: Underlying mechanisms. Cardiovasc. Diabetol. 2012, 11, 129.
33. Nunes, S.; Soares, E.; Fernandes, J.; Viana, S.; Carvalho, E.; Pereira, F.C.; Reis, F. Early cardiac changes in a rat model of prediabetes: Brain natriuretic peptide overexpression seems to be the best marker. Cardiovasc. Diabetol. 2013, 12, 44.
34. . Bugger, H.; Abel, E.D. Rodent models of diabetic cardiomyopathy. Dis. Model. Mech. 2009, 2, 454-466.
35. Wang, P.; Lloyd, S.G.; Zeng, H.; Bonen, A.; Chatham, J.C. Impact of altered substrate utilization on cardiac function in isolated hearts from Zucker diabetic fatty rats. Am. J. Physiol. Heart Circ. Physiol. 2005, 288, 2102-2110.
36. Chen, W.; Xia, Y.; Zhao, X.; Wang, H.; Yu, M.; Li, Y.; Ye, H.; Zhang, Y. The critical role of astragalus polysaccharides for the improvement of PPARalpha [correction of PPRAalpha]-mediated lipotoxicity in diabetic cardiomyopathy. PLoS One 2012, 7, e45541.
37. Mihm, M.J.; Seifert, J.L.; Coyle, C.M.; Bauer, J.A. Diabetes related cardiomyopathy time dependent echocardiographic evaluation in an experimental rat model. Life Sci. 2001, 69, 527-542.
38. Brownlee, M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005, 54, 1615-1625.
39. Shrimali, D.; Shanmugam, M.K.; Kumar, A.P.; Zhang, J.; Tan, B.K.; Ahn, K.S.; Sethi, G. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett. 2013, 341, 139-149.
40. National Toxicology Program. NTP toxicology and carcinogenesis studies of emodin (CAS NO. 518-82-1) feed studies in F344/N rats and B6C3F1 mice. Natl. Toxicol. Program. Tech. Rep. Ser. 2001, 493, 1-278.
41. Wang, Y.; Feng, W.; Xue, W.; Tan, Y.; Hein, D.W.; Li, X.K.; Cai, L. Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling. Diabetes 2009, 58, 1391-1402.
42. Katare, R.G.; Caporali, A.; Oikawa, A.; Meloni, M.; Emanueli, C.; Madeddu, P. Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway. Circ. Heart Fail. 2010, 3, 294-305.
43. Sun, D.; Shen, M.; Li, J.; Li, W.; Zhang, Y.; Zhao, L.; Zhang, Z.; Yuan, Y.; Wang, H.; Cao, F. Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3? dependent pathway in experimental diabetic cardiomyopathy. Cardiovasc. Diabetol. 2011, 10, 4.
44. Zhang, Y.; Babcock, S.A.; Hu, N.; Maris, J.R.; Wang, H.; Ren, J. Mitochondrial aldehyde dehydrogenase (ALDH2) protects against streptozotocin-induced diabetic cardiomyopathy: Role of GSK3-and mitochondrial function. BMC Med. 2012, 10, 40.
45. . Salloum, F.N.; Chau, V.Q.; Hoke, N.N.; Abbate, A.; Varma, A.; Ockaili, R.A.; Toldo, S.; Kukreja, R.C. Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide. Circulation 2009, 120, 31-36.
46. Lin, Y.C.; Leu, S.; Sun, C.K.; Yen, C.H.; Kao, Y.H.; Chang, L.T.; Tsai, T.H.; Chua, S.; Fu, M.; Ko, S.F.; et al. Early combined treatment with sildenafil and adipose-derived mesenchymal stem cells preserves heart function in rat dilated cardiomyopathy. J. Transl. Med. 2010, 8, 88.